Want to join the conversation?
$BSX's selling, general and administrative (SG&A) expenses for 1Q16 increased by 7% from last year and were 130 basis points lower as percentage of net sales. The decline in SG&A as percentage of sales was due to recent suspension of medical device tax, as well as targeted initiatives that have been focused on reducing SG&A.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.